Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/31/09
End: 09/30/10
Due: 09/30/11
Phase: N/A
Priority: Normal
Start: 08/31/09
End: 04/30/10
Due: 04/30/11
Phase: N/A
Priority: Normal
Start: 03/31/08
End: 01/31/09
Due: 01/31/10
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients | NCT00715364 | Stem Cell Therapeutics Corp. | user2@example.com | None | 2009-08-31 | 2010-09-30 | 2011-09-30 | - | - | 2025-07-14 |
| Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients | NCT00938314 | Stem Cell Therapeutics Corp. | user2@example.com | None | 2009-08-31 | 2010-04-30 | 2011-04-30 | - | - | 2025-07-14 |
| REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients | NCT00663416 | Stem Cell Therapeutics Corp. | user2@example.com | None | 2008-03-31 | 2009-01-31 | 2010-01-31 | - | - | 2025-07-14 |